Lag in U.S. recall highlights strains in global pharmaceutical supply chain.
A Chinese-made heart drug taken by millions of people was contaminated with a possible cancer-causing chemical.
The Food and Drug Administration oversaw a recall of the tainted pills. But even as it did so, the agency that helps safeguard a global supply chain of drugs was conducting fewer inspections of pharmaceutical plants in the country where the problem originated.
Johnson & Johnson says its Baby Powder is safe. But Reuters found its talc was sometimes tainted with asbestos, a fact it kept from regulators and the public.
Darlene Coker knew she was dying. She just wanted to know why.
She knew that her cancer, mesothelioma, arose in the delicate membrane surrounding her lungs and other organs. She knew it was as rare as it was deadly, a signature of exposure to asbestos. And she knew it afflicted mostly men who inhaled asbestos dust in mines and industries such as shipbuilding that used the carcinogen before its risks were understood.
Three Xarelto lawsuits are headed to trial starting next month in the Philadelphia Court of Common Pleas, the home of a mass tort program that includes more than 1,700 product liability claims involving the controversial blood-thinning medication. (In Re: Xarelto Litigation, Case No. 150102349)
Pennsylvania concluded its first Xarelto trial late last year, when a Philadelphia jury awarded $28 million in compensatory and punitive damages to an Indiana woman who suffered a gastrointestinal bleed after taking the medication for a little over a year. However, the trial court dismissed the verdict in January, after finding that the evidence presented was insufficient to justify the massive award.
A Pennsylvania jury hearing evidence in the state’s first trial of a Xarelto lawsuit has awarded $28 million to an Indiana woman who suffered a gastrointestinal bleeding a little over a year after she was prescribed the new-generation blood thinner.
The judge overseeing the Xarelto mass tort in Philadelphia is considering a flurry of motions and responses that are expected to shape the state court litigation as it is gearing up for next month’s bellwether trial.
Lawyer Advertising. This website is designed for general information only, and in no way is intended to constitute legal advice nor the formation of a lawyer/client relationship without a signed, written agreement. Testimonials or endorsements do not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter. You pay no fees or costs unless we recover for you. This website contains dramatizations. Prior results are not a guarantee of a future outcome. Jacoby & Meyers does not accept all cases and works cooperatively with co-counsel and/or other law firms with whom it has joint agreements who might potentially handle your cases. We look forward to helping you with your claim.